High Growth Tech Stocks In South Korea For October 2024

The South Korean market has shown a positive trend, increasing by 1.1% over the last week and climbing 4.9% in the past year, with earnings forecasted to grow by 30% annually. In this environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation and adaptability to capitalize on these favorable market conditions.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
IMLtd	21.80%	111.43%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Park Systems	23.21%	34.63%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 48 stocks from our KRX High Growth Tech and AI Stocks screener.

Here's a peek at a few of the choices from the screener.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company that specializes in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩20.53 trillion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 million. Its focus on developing specialized biopharmaceutical products positions it within the biotech industry.

ALTEOGEN is navigating the competitive biotech landscape with a strategic focus on R&D, channeling significant investments into innovation. In 2024, its R&D expenses surged to 20% of total revenue, reflecting a commitment to developing cutting-edge solutions. This investment is pivotal as the company anticipates revenue growth at an impressive rate of 64.2% annually, outpacing the broader South Korean market's growth forecast of 10.4%. Despite current unprofitability, ALTEOGEN's aggressive growth strategy and R&D focus are set to drive its transition to profitability with expected earnings growth rocketing by 99.5% per year. This positions ALTEOGEN uniquely within high-growth sectors, potentially leading to substantial market share expansion as it matures into profitability over the next three years.

• Take a closer look at ALTEOGEN's potential here in our health report.

• Examine ALTEOGEN's past performance report to understand how it has performed in the past.

ISU Petasys (KOSE:A007660)

Simply Wall St Growth Rating: ★★★★★☆

Overview: ISU Petasys Co., Ltd. is a global manufacturer and seller of printed circuit boards (PCBs) with a market capitalization of ₩2.70 trillion.

Operations: ISU Petasys generates revenue primarily through the manufacture and sale of printed circuit boards, contributing ₩743.88 billion to its financial performance. The company's market capitalization stands at ₩2.70 trillion, reflecting its significant presence in the global PCB market.

ISU Petasys is capitalizing on the robust demand for advanced tech components, with a notable revenue growth forecast at 18.6% annually, outpacing South Korea's market average of 10.4%. This growth trajectory is underpinned by a significant commitment to research and development, with R&D expenses reaching 44.4% of total revenue, highlighting an aggressive strategy to innovate within the electronic segment. Despite challenges such as a highly volatile share price and lower profit margins year-over-year—7.5% compared to last year’s 12.6%—the company's focus on enhancing its technological offerings could position it well for future profitability, especially given the projected earnings growth of 44.38% per year.

• Get an in-depth perspective on ISU Petasys' performance by reading our health report here.

• Understand ISU Petasys' track record by examining our Past report.

Celltrion (KOSE:A068270)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, focuses on developing and manufacturing protein-based drugs for oncology treatment in South Korea, with a market capitalization of ₩41.37 trillion.

Operations: The primary revenue stream for Celltrion, Inc. comes from its Bio Medical Supply segment, generating ₩3.54 trillion. Additionally, the Chemical Drugs segment contributes ₩507 billion to its revenue model.

Celltrion's trajectory in the biotech sector is marked by robust revenue growth of 25.6% annually, outstripping South Korea's market average of 10.4%. This growth is fueled by strategic R&D investments, which account for a substantial portion of their expenses, aligning with their commitment to innovation in biopharmaceuticals. Recent announcements reveal significant advancements, such as the extended efficacy of their subcutaneous infliximab and new agreements enhancing U.S. market penetration. Despite facing challenges like a recent earnings dip and share repurchases totaling KRW 75.89 billion this year, Celltrion's forward-looking initiatives suggest potential for sustained impact in global healthcare markets.

• Click to explore a detailed breakdown of our findings in Celltrion's health report.

• Assess Celltrion's past performance with our detailed historical performance reports.

Where To Now?

• Unlock more gems! Our KRX High Growth Tech and AI Stocks screener has unearthed 45 more companies for you to explore.Click here to unveil our expertly curated list of 48 KRX High Growth Tech and AI Stocks.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com